Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$-2.29
EPS est.
$-3.00
EPS surprise
+23.67%
1-day move
-2.26%
GRAIL, Inc. reported a wider loss than expected in EPS, which may raise concerns among investors about the company's financial health. The stock reacted negatively, declining by 2.26%. The absence of revenue figures and guidance adds uncertainty regarding future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.29 | $-1.96 | +23.67% |
| Revenue | — | $39M | — |
No transcript is on record, and the analysis is based on numerical results only.
GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests. As part of the health care sector, GRAIL aims to improve patient outcomes by identifying cancers at earlier stages, which is a significant theme in the ongoing fight against cancer.
Last quarter
In the last quarter, GRAIL reported an EPS of $-2.44, which was better than analysts' expectations. However, revenue details were not disclosed, leading to a mixed market reaction.
Management promises and guidance
EPS beat streak
7Q
EPS beat rate
88%
Avg EPS surprise
+20.18%
Avg 1-day reaction
+1.51%
Analysts expect GRAIL to report a loss this quarter, but there is hope for improved revenue as the company continues to develop its product offerings.
Bull case
If GRAIL can exceed revenue expectations and show signs of narrowing losses, it could signal a turning point for investor confidence.
Bear case
If GRAIL fails to meet revenue expectations or reports a wider loss, it could raise concerns about its long-term viability and market strategy.
Key metrics to watch
EPS
$-1.96Earnings per share is a key indicator of profitability, and this quarter's estimate reflects ongoing challenges in achieving profitability.
Revenue
$39MRevenue growth is crucial for GRAIL as it seeks to establish its market presence and validate its business model.
The print will turn on these.
Q1
Will GRAIL achieve revenue of at least $39M this quarter?
Meeting or exceeding this revenue target is crucial for demonstrating growth and market acceptance of their technology.
Q2
What specific steps is GRAIL taking to reduce its EPS loss this quarter?
Investors will want to understand the company's strategy for improving profitability and managing costs.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may underestimate GRAIL's potential for revenue growth due to its unique position in early cancer detection, which could lead to stronger-than-expected demand.
Supporting evidence
GRAIL's innovative technology may capture market share faster than anticipated.
The options market indicates a significant expected move, suggesting that traders believe in potential volatility.
Past earnings surprises show GRAIL has consistently beaten EPS estimates, indicating potential for positive surprises.
Key risk
If revenue comes in below $37M, it could raise serious doubts about GRAIL's growth trajectory.
Pre-commit to what would confirm each case.
The market is debating GRAIL's ability to grow revenue while managing losses, making these metrics pivotal.
Bull confirmed if
Revenue exceeding $39M with a narrowing EPS loss would confirm the bull case.
Bear confirmed if
An EPS loss greater than $-2.54 would support the bear case.
What the market is pricing for the move.
Implied Move
±12.8%
Historical Avg
±4.9%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.
Options are pricing ±12.8% while GRAL has averaged ±4.9% over the last 8 prints — setup is pricing rich.
ATM IV
1.2%
30d HV
76.6%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$4.6M
31,492 sh
2 insiders
Net
$4.6M
Net selling
Most Active Insiders· 2 open-market trades
$3.5M
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If GRAIL beats expectations, history suggests a positive reaction, with an average 1-day move of +2.74%, confirming growth potential.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.
Miss
A miss could lead to a negative reaction, with historical data suggesting a potential average drop of around 5.82%.
The lines on the call that would change the story.
$1.2M
Net selling
Recent Transactions
Oct 5, 2026 · @ $146.39
23,619 sh
$3.5M
Oct 5, 2026 · @ $146.39
7,873 sh
$1.2M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.